NASDAQ:MRUS
Merus NV Stock News
$43.91
-1.11 (-2.47%)
At Close: May 17, 2024
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
10:48pm, Thursday, 05'th Aug 2021
Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Second Quarter and Provides Business Update
05:00pm, Thursday, 05'th Aug 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company d
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with con
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, wit
Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last?
12:47pm, Wednesday, 19'th May 2021
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates
08:17pm, Thursday, 06'th May 2021
Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the First Quarter and Provides Business Update
05:14pm, Thursday, 06'th May 2021
Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., prom
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
04:01pm, Wednesday, 28'th Apr 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
04:57pm, Tuesday, 16'th Mar 2021
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
04:45pm, Wednesday, 10'th Mar 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
08:00am, Monday, 08'th Mar 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodi
Merus Announces Pricing of Public Offering of Common Shares
08:41am, Thursday, 21'st Jan 2021
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovati
Merus N.V. Announces Proposed Public Offering of Common Shares
04:18pm, Tuesday, 19'th Jan 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovativ
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
10:50am, Tuesday, 19'th Jan 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
06:30am, Tuesday, 19'th Jan 2021
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a